Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
NRIX on Nasdaq
Shares outstanding
104,555,500
Price per share
$19.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
113,319,318
Total reported value
$2,149,653,362
% of total 13F portfolios
0%
Share change
+26,583,661
Value change
+$525,806,070
Number of holders
179
Price from insider filings
$19.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 7.2% $138,364,566 7,527,996 Baker Bros. Advisors LP 31 Dec 2025
BlackRock, Inc. 8.2% $72,644,381 6,284,116 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.2% +35% $63,580,000 +$15,895,000 5,500,000 +33% Deep Track Capital, LP 31 Mar 2025
FMR LLC 4.1% -62% $38,437,849 -$42,758,996 4,159,940 -53% FMR LLC 31 Oct 2025
Commodore Capital LP 4.9% -4% $34,927,708 -$646,292 3,780,055 -1.8% Commodore Capital LP 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 4.2% $36,861,858 3,188,742 Wellington Management Group LLP 31 Mar 2025

As of 31 Dec 2025, 179 institutional investors reported holding 113,319,318 shares of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX). This represents 108% of the company’s total 104,555,500 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.5% 8,875,194 +31% 0% $168,362,430
Redmile Group, LLC 7.7% 8,093,908 +120% 11% $153,541,435
Deep Track Capital, LP 6.7% 7,036,455 +16% 3% $133,481,551
VANGUARD GROUP INC 5.7% 5,949,512 +33% 0% $112,862,243
GENERAL ATLANTIC, L.P. 4.7% 4,897,159 3.2% $92,899,106
MORGAN STANLEY 4.7% 4,881,068 +116% 0.01% $92,593,872
Vestal Point Capital, LP 4.5% 4,690,000 +35% 3.3% $88,969,300
BAKER BROS. ADVISORS LP 4.5% 4,658,556 +20% 0.52% $88,372,807
FMR LLC 4% 4,234,158 -52% 0% $80,321,977
STATE STREET CORP 3.4% 3,559,501 +24% 0% $67,523,734
PERCEPTIVE ADVISORS LLC 3.4% 3,555,877 +151% 1.2% $67,454,987
Pictet Asset Management Holding SA 3.3% 3,467,600 +75% 0.06% $65,780,372
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 3,248,361 +196% 0.01% $61,622,000
Point72 Asset Management, L.P. 3.1% 3,211,680 +12% 0.1% $60,925,570
DEUTSCHE BANK AG\ 2.4% 2,486,792 +73% 0.02% $47,174,444
Rubric Capital Management LP 2.4% 2,473,885 0.56% $46,929,598
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,384,998 +27% 0% $45,250,415
Commodore Capital LP 2.2% 2,275,000 -40% 2.9% $43,156,750
BRAIDWELL LP 2.1% 2,183,864 1.3% $41,427,900
Kynam Capital Management, LP 1.9% 1,970,357 -9.1% 2.4% $37,377,672
Trails Edge Capital Partners, LP 1.7% 1,743,220 0% 8.2% $33,068,884
ARK Investment Management LLC 1.5% 1,602,539 +6.1% 0.2% $30,400,171
EVENTIDE ASSET MANAGEMENT, LLC 1.2% 1,297,893 0.38% $24,621,030
Sumitomo Mitsui Trust Group, Inc. 1.2% 1,290,554 -17% 0.01% $24,481,809
Amova Asset Management Americas, Inc. 1.2% 1,290,554 -17% 0.28% $24,481,809

Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 113,319,318 $2,149,653,362 +$525,806,070 $18.97 179
2025 Q3 84,776,704 $783,330,709 -$36,480,185 $9.24 171
2025 Q2 88,319,847 $1,005,944,844 +$40,932,248 $11.39 161
2025 Q1 84,604,598 $1,005,122,777 +$28,667,924 $11.88 168
2024 Q4 81,104,522 $1,528,053,172 +$225,677,197 $18.84 173
2024 Q3 67,877,304 $1,525,459,447 +$59,100,303 $22.47 170
2024 Q2 64,996,165 $1,356,466,249 +$340,051,233 $20.87 172
2024 Q1 49,045,600 $720,957,554 +$50,639,301 $14.70 138
2023 Q4 46,078,653 $475,525,962 +$17,732,104 $10.32 127
2023 Q3 44,845,094 $352,482,854 +$8,466,362 $7.86 129
2023 Q2 43,637,466 $435,668,849 +$11,852,256 $9.99 124
2023 Q1 42,478,076 $376,567,538 -$3,101,624 $8.88 121
2022 Q4 42,696,157 $468,798,220 +$2,144,188 $10.98 119
2022 Q3 43,069,388 $561,182,776 -$38,324,545 $13.03 114
2022 Q2 44,940,935 $567,552,048 +$55,435,115 $12.67 100
2022 Q1 40,367,078 $565,503,716 -$19,332,926 $14.01 111
2021 Q4 40,421,865 $1,170,057,078 +$25,875,537 $28.95 121
2021 Q3 39,378,816 $1,180,362,633 -$11,970,711 $29.96 110
2021 Q2 39,520,770 $1,048,795,893 -$66,662,023 $26.53 103
2021 Q1 41,346,108 $1,285,407,277 +$254,357,641 $31.09 99
2020 Q4 33,136,833 $1,089,462,176 +$26,868,033 $32.88 67
2020 Q3 31,854,383 $1,111,189,598 +$1,111,189,598 $34.91 64